董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Sukumar Nagendran | 男 | Director and President and Head of Research and Development | 56 | 209.29万美元 | 118.35 | 2023-04-27 |
| Kathleen Reape | 女 | Director | 57 | 7.22万美元 | 未持股 | 2023-04-27 |
| Laura Sepp Lorenzino | 女 | Director | 62 | 45.06万美元 | 24.59 | 2023-04-27 |
| Phillip B. Donenberg | 男 | Director | 62 | 44.56万美元 | 36.81 | 2023-04-27 |
| Paul B. Manning | 男 | Director | 67 | 7.21万美元 | 未持股 | 2023-04-27 |
| Sean P. Nolan | 男 | Chief Executive Officer and Chairman of Board | 55 | 409.91万美元 | 448.05 | 2023-04-27 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Sukumar Nagendran | 男 | Director and President and Head of Research and Development | 56 | 209.29万美元 | 118.35 | 2023-04-27 |
| Kamran Alam | 男 | Chief Financial Officer | 45 | 214.70万美元 | 160.68 | 2023-04-27 |
| Sean P. Nolan | 男 | Chief Executive Officer and Chairman of Board | 55 | 409.91万美元 | 448.05 | 2023-04-27 |
董事简历
中英对照 | 中文 | 英文- Sukumar Nagendran
-
Sukumar Nagendran自2020年7月以来一直担任我们的董事会成员。Nagendran博士自2018年9月起担任生命科学公司Solid BiosciencesInc.的董事会成员，目前担任生物技术公司Encode Therapeutics，Inc.的顾问。在与Immunovant，Inc.合并之前，他曾于2019年3月至2019年12月担任特殊目的收购公司Health Sciences Acquisition Corp.的董事会成员。Nagendran博士最近于2015年9月至2018年5月担任基因治疗公司Avexis，Inc.（Quest Diagnostics Inc.）的高级副总裁兼首席医疗官，此前曾担任临床实验室Quest Diagnostics Inc.美国和国际业务主管Vice President，从2013年3月到2015年9月。Nagendran博士在罗格斯大学（Rutgers University）获得文学学士学位，在新泽西医学和牙科大学（University of Medicine and Dentistry of New Jersey）获得医学硕士学位，并在明尼苏达州罗彻斯特的梅奥诊所（Mayo Clinic）接受内科培训。
Sukumar Nagendran,has served as Taysha Gene Therapies, Inc. President and Head of Research and Development since December 2022 and as a member of Taysha Gene Therapies, Inc. Board of Directors since July 2020. Dr. Nagendran previously served as President, Research and Development and Chief Medical Officer at Jaguar Gene Therapy, LLC, from February 2020 to December 2022. Dr. Nagendran has served on the board of directors of Solid Biosciences Inc., a publicly traded life sciences company, since September 2018 and currently serves as an advisor to Encoded Therapeutics, Inc., a biotechnology company. He previously served on the board of directors of Health Sciences Acquisition Corp., a special purpose acquisition company, from March 2019 to December 2019 prior to its merger with Immunovant, Inc. Dr. Nagendran most recently served as Senior Vice President and Chief Medical Officer of AveXis, Inc., a publicly traded gene therapy company, from 2015 to May 2018. Dr. Nagendran earned a B.A. from Rutgers University and an M.D. from the University of Medicine and Dentistry of New Jersey and trained in Internal Medicine at Mayo Clinic in Rochester, Minnesota. - Sukumar Nagendran自2020年7月以来一直担任我们的董事会成员。Nagendran博士自2018年9月起担任生命科学公司Solid BiosciencesInc.的董事会成员，目前担任生物技术公司Encode Therapeutics，Inc.的顾问。在与Immunovant，Inc.合并之前，他曾于2019年3月至2019年12月担任特殊目的收购公司Health Sciences Acquisition Corp.的董事会成员。Nagendran博士最近于2015年9月至2018年5月担任基因治疗公司Avexis，Inc.（Quest Diagnostics Inc.）的高级副总裁兼首席医疗官，此前曾担任临床实验室Quest Diagnostics Inc.美国和国际业务主管Vice President，从2013年3月到2015年9月。Nagendran博士在罗格斯大学（Rutgers University）获得文学学士学位，在新泽西医学和牙科大学（University of Medicine and Dentistry of New Jersey）获得医学硕士学位，并在明尼苏达州罗彻斯特的梅奥诊所（Mayo Clinic）接受内科培训。
- Sukumar Nagendran,has served as Taysha Gene Therapies, Inc. President and Head of Research and Development since December 2022 and as a member of Taysha Gene Therapies, Inc. Board of Directors since July 2020. Dr. Nagendran previously served as President, Research and Development and Chief Medical Officer at Jaguar Gene Therapy, LLC, from February 2020 to December 2022. Dr. Nagendran has served on the board of directors of Solid Biosciences Inc., a publicly traded life sciences company, since September 2018 and currently serves as an advisor to Encoded Therapeutics, Inc., a biotechnology company. He previously served on the board of directors of Health Sciences Acquisition Corp., a special purpose acquisition company, from March 2019 to December 2019 prior to its merger with Immunovant, Inc. Dr. Nagendran most recently served as Senior Vice President and Chief Medical Officer of AveXis, Inc., a publicly traded gene therapy company, from 2015 to May 2018. Dr. Nagendran earned a B.A. from Rutgers University and an M.D. from the University of Medicine and Dentistry of New Jersey and trained in Internal Medicine at Mayo Clinic in Rochester, Minnesota.
- Kathleen Reape
-
Kathleen Reape，自2020年11月起担任Taysha Gene Therapies, Inc.董事会成员。Reape博士自2021年5月起担任基因治疗公司Akouos, Inc.的首席开发官。她于2018年9月至2020年3月担任星火治疗公司首席医疗官，并于2016年至2018年9月担任临床研发主管。Reape博士在宾夕法尼亚大学获得了本科和医学博士学位，并在佛罗里达大学和新泽西医学与牙科大学完成了实习和实习。
Kathleen Reape,has served as a member of Taysha Gene Therapies, Inc. Board of Directors since November 2020. Dr. Reape has served as the Chief Development Officer of Akouos, Inc., a gene therapy company, since May 2021. She served as Chief Medical Officer of Spark Therapeutics, Inc. from September 2018 to March 2020 and as the Head of Clinical Research and Development from 2016 to September 2018. Dr. Reape received both her undergraduate and M.D. degrees from the University of Pennsylvania and completed her internship and residency at the University of Florida and University of Medicine and Dentistry of New Jersey. - Kathleen Reape，自2020年11月起担任Taysha Gene Therapies, Inc.董事会成员。Reape博士自2021年5月起担任基因治疗公司Akouos, Inc.的首席开发官。她于2018年9月至2020年3月担任星火治疗公司首席医疗官，并于2016年至2018年9月担任临床研发主管。Reape博士在宾夕法尼亚大学获得了本科和医学博士学位，并在佛罗里达大学和新泽西医学与牙科大学完成了实习和实习。
- Kathleen Reape,has served as a member of Taysha Gene Therapies, Inc. Board of Directors since November 2020. Dr. Reape has served as the Chief Development Officer of Akouos, Inc., a gene therapy company, since May 2021. She served as Chief Medical Officer of Spark Therapeutics, Inc. from September 2018 to March 2020 and as the Head of Clinical Research and Development from 2016 to September 2018. Dr. Reape received both her undergraduate and M.D. degrees from the University of Pennsylvania and completed her internship and residency at the University of Florida and University of Medicine and Dentistry of New Jersey.
- Laura Sepp Lorenzino
-
Laura Sepp Lorenzino，自2020年11月起担任Taysha Gene Therapies, Inc.董事会成员。自2019年5月起担任上市生物技术公司Intellia Therapeutics, Inc.执行副总裁兼首席科学官。从2017年到2019年5月，Sepp-Lorenzino博士担任上市生物制药公司福泰制药的副总裁兼核酸治疗主管。2014年至2017年，她在上市生物制药公司Alnylam Pharmaceuticals, Inc.担任常驻企业家副总裁。Sepp-Lorenzino博士在阿根廷布宜诺斯艾利斯大学获得生物化学专业学位，在纽约大学获得生物化学硕士和博士学位。
Laura Sepp Lorenzino,has served as a member of Taysha Gene Therapies, Inc. Board of Directors since November 2020.Dr. Sepp-Lorenzino has served as Intellia Therapeutics, Inc. executive vice president, chief scientific officer since May 2019.Prior to joining Intellia, Dr. Sepp-Lorenzino was vice president, head of nucleic acid therapies, research, and a member of the research leadership and external innovation team at Vertex from September 2017 to May 2019. From April 2014 to September 2017, Dr. Sepp-Lorenzino was vice president, entrepreneur-in-residence and head of the hepatic infectious disease strategic therapeutic area at Alnylam Pharmaceuticals, Inc. She is a member of the board of directors of Taysha Gene Therapies Inc., the Alliance for Regenerative Medicine and the Oligonucleotide Therapeutics Society and sits on the scientific advisory boards of Thermo Fisher Scientific Inc., the U.K. Nucleic Acid Therapy Accelerator and Arsenal Capital Partners. She is also a member of the Editorial Board of Nucleic Acid Therapeutics. Dr. Sepp-Lorenzino earned a professional degree in biochemistry from the Universidad de Buenos Aires in Argentina and a Ph.D. in biochemistry from New York University. - Laura Sepp Lorenzino，自2020年11月起担任Taysha Gene Therapies, Inc.董事会成员。自2019年5月起担任上市生物技术公司Intellia Therapeutics, Inc.执行副总裁兼首席科学官。从2017年到2019年5月，Sepp-Lorenzino博士担任上市生物制药公司福泰制药的副总裁兼核酸治疗主管。2014年至2017年，她在上市生物制药公司Alnylam Pharmaceuticals, Inc.担任常驻企业家副总裁。Sepp-Lorenzino博士在阿根廷布宜诺斯艾利斯大学获得生物化学专业学位，在纽约大学获得生物化学硕士和博士学位。
- Laura Sepp Lorenzino,has served as a member of Taysha Gene Therapies, Inc. Board of Directors since November 2020.Dr. Sepp-Lorenzino has served as Intellia Therapeutics, Inc. executive vice president, chief scientific officer since May 2019.Prior to joining Intellia, Dr. Sepp-Lorenzino was vice president, head of nucleic acid therapies, research, and a member of the research leadership and external innovation team at Vertex from September 2017 to May 2019. From April 2014 to September 2017, Dr. Sepp-Lorenzino was vice president, entrepreneur-in-residence and head of the hepatic infectious disease strategic therapeutic area at Alnylam Pharmaceuticals, Inc. She is a member of the board of directors of Taysha Gene Therapies Inc., the Alliance for Regenerative Medicine and the Oligonucleotide Therapeutics Society and sits on the scientific advisory boards of Thermo Fisher Scientific Inc., the U.K. Nucleic Acid Therapy Accelerator and Arsenal Capital Partners. She is also a member of the Editorial Board of Nucleic Acid Therapeutics. Dr. Sepp-Lorenzino earned a professional degree in biochemistry from the Universidad de Buenos Aires in Argentina and a Ph.D. in biochemistry from New York University.
- Phillip B. Donenberg
-
Phillip B. Donenberg，是一位注册会计师，从2010年8月开始担任 BioSante金融部的高级副总裁，从1998年开始担任首席财务官和秘书。在加入BioSante之前，从1995年到1998年，Donenberg先生是Unimed Pharmaceuticals,Inc.的财务总监，该公司目前是AbbVie Inc.的全资子公司。在加入Unimed Pharmaceuticals, Inc.之前，Donenberg先生在其他的制药公司担任了各种相似的职位，包括在Gynex Pharmaceuticals,Inc.（目前更名为Savient Pharmaceuticals, Inc.），Applied NeuroSolutions,Inc.（之前称为 Molecular Geriatrics Corporation）和Xtramedics,Inc.任职。
Phillip B. Donenberg has served as a member of Faeth Therapeutics, Inc.'s board of directors since February 2026. He has served as a member of the board of directors, member of the compensation committee and chairman of the audit committee of Taysha Gene Therapies, Inc., a publicly traded biotechnology company, since August 2020, and as a member of the board of directors and chairman of the audit committee of Tectonic Therapeutic, Inc. (formerly AVROBIO, Inc.), a publicly traded biotechnology company, since June 2018. He served as Senior Vice President and Chief Financial Officer of Jaguar Gene Therapy, LLC from February 2020 to March 2023. Previously, Mr. Donenberg served as Chief Financial Officer and Senior Vice President of Assertio Therapeutics, Inc., a publicly traded biotechnology company. He served as Senior Vice President and Chief Financial Officer of AveXis, Inc., a publicly traded biotechnology company, from 2017 to June 2018, and as Vice President, Corporate Controller from 2016 to 2017. Mr. Donenberg earned a B.S. in accountancy from the University of Illinois Champaign Urbana College of Business and is a Certified Public Accountant. - Phillip B. Donenberg，是一位注册会计师，从2010年8月开始担任 BioSante金融部的高级副总裁，从1998年开始担任首席财务官和秘书。在加入BioSante之前，从1995年到1998年，Donenberg先生是Unimed Pharmaceuticals,Inc.的财务总监，该公司目前是AbbVie Inc.的全资子公司。在加入Unimed Pharmaceuticals, Inc.之前，Donenberg先生在其他的制药公司担任了各种相似的职位，包括在Gynex Pharmaceuticals,Inc.（目前更名为Savient Pharmaceuticals, Inc.），Applied NeuroSolutions,Inc.（之前称为 Molecular Geriatrics Corporation）和Xtramedics,Inc.任职。
- Phillip B. Donenberg has served as a member of Faeth Therapeutics, Inc.'s board of directors since February 2026. He has served as a member of the board of directors, member of the compensation committee and chairman of the audit committee of Taysha Gene Therapies, Inc., a publicly traded biotechnology company, since August 2020, and as a member of the board of directors and chairman of the audit committee of Tectonic Therapeutic, Inc. (formerly AVROBIO, Inc.), a publicly traded biotechnology company, since June 2018. He served as Senior Vice President and Chief Financial Officer of Jaguar Gene Therapy, LLC from February 2020 to March 2023. Previously, Mr. Donenberg served as Chief Financial Officer and Senior Vice President of Assertio Therapeutics, Inc., a publicly traded biotechnology company. He served as Senior Vice President and Chief Financial Officer of AveXis, Inc., a publicly traded biotechnology company, from 2017 to June 2018, and as Vice President, Corporate Controller from 2016 to 2017. Mr. Donenberg earned a B.S. in accountancy from the University of Illinois Champaign Urbana College of Business and is a Certified Public Accountant.
- Paul B. Manning
-
PaulB.Manning自2020年3月以来一直担任我们的董事会成员。Manning先生目前担任PBM Capital Group，LLC的首席执行官，这是一家私募股权投资公司，其业务是投资于梦百合和生命科学相关公司，该公司由他于2010年创立。Manning先生目前担任Verrica PharmaceuticalsInc.公司（一家生物制药公司）董事会主席。此外，他曾于2016年9月至2019年11月担任生物制药公司Dova制药有限公司的董事会成员，并于2014年4月至2018年5月担任基因治疗公司Avexis，Inc.的董事会成员。Manning先生在马萨诸塞大学（University of Massachusetts）获得微生物学学士学位。
Paul B. Manning,has served as a member of Taysha Gene Therapies, Inc. Board of Directors since March 2020. Mr. Manning currently serves as the Chief Executive Officer of PBM Capital Group, LLC, a private equity investment firm in the business of investing in healthcare and life-science related companies, which he founded in 2010. Mr. Manning has served as interim Chief Executive Officer of SalioGen Therapeutics, Inc., a private biopharmaceutical company, since November 2022. Mr. Manning currently serves as Chairman of the board of directors of Verrica Pharmaceuticals Inc., a publicly traded biopharmaceutical company, and on the boards of directors of Liquidia Corporation, a publicly traded biopharmaceutical company, and Candel Therapeutics, Inc., a publicly traded biopharmaceutical company. Additionally, he previously served on the boards of directors of Dova Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, from 2016 to November 2019 and AveXis, Inc., a publicly traded gene therapy company, from 2014 to May 2018. Mr. Manning earned a B.S. in microbiology from the University of Massachusetts. - PaulB.Manning自2020年3月以来一直担任我们的董事会成员。Manning先生目前担任PBM Capital Group，LLC的首席执行官，这是一家私募股权投资公司，其业务是投资于梦百合和生命科学相关公司，该公司由他于2010年创立。Manning先生目前担任Verrica PharmaceuticalsInc.公司（一家生物制药公司）董事会主席。此外，他曾于2016年9月至2019年11月担任生物制药公司Dova制药有限公司的董事会成员，并于2014年4月至2018年5月担任基因治疗公司Avexis，Inc.的董事会成员。Manning先生在马萨诸塞大学（University of Massachusetts）获得微生物学学士学位。
- Paul B. Manning,has served as a member of Taysha Gene Therapies, Inc. Board of Directors since March 2020. Mr. Manning currently serves as the Chief Executive Officer of PBM Capital Group, LLC, a private equity investment firm in the business of investing in healthcare and life-science related companies, which he founded in 2010. Mr. Manning has served as interim Chief Executive Officer of SalioGen Therapeutics, Inc., a private biopharmaceutical company, since November 2022. Mr. Manning currently serves as Chairman of the board of directors of Verrica Pharmaceuticals Inc., a publicly traded biopharmaceutical company, and on the boards of directors of Liquidia Corporation, a publicly traded biopharmaceutical company, and Candel Therapeutics, Inc., a publicly traded biopharmaceutical company. Additionally, he previously served on the boards of directors of Dova Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, from 2016 to November 2019 and AveXis, Inc., a publicly traded gene therapy company, from 2014 to May 2018. Mr. Manning earned a B.S. in microbiology from the University of Massachusetts.
- Sean P. Nolan
-
Sean P. Nolan，Nolan Capital, LLC（投资基金）总裁，2019年至今。AveXis, Inc.（前纳斯达克股票代码：AVXS）的总裁兼首席执行官（2015年至2018年）。他自2013年2月加入InterMune起担任其执行副总裁兼首席业务官。在加入InterMune前，自2011年8月至2012年12月他在Reata Pharmaceuticals Inc.担任副总裁兼首席商务官。先前自2004年起他在Ovation Pharmaceuticals担任市场营销和销售运营部副总裁。2009年Ovation被丹麦制药公司H. Lundbeck收购。在2009年4月至2010年10月期间领导Ovation的一体化后，他担任首席商务官以及之后Lundbeck新创建美国实体的总裁。他持有来自John Carroll University的生物学文学士学位。
Sean P. Nolan has to Board 35 years of experience in the life sciences industry as a public company executive, operator and serial entrepreneur. His diverse functional expertise includes commercial operations, global marketing, and corporate and business development. Mr. Nolan previously served as CEO of AveXis (NYSE: AVXS), which he grew from four employees to a fully integrated global public company with research, clinical, regulatory, manufacturing and commercial operations that was ultimately sold to Novartis for $8.7 billion. - Sean P. Nolan，Nolan Capital, LLC（投资基金）总裁，2019年至今。AveXis, Inc.（前纳斯达克股票代码：AVXS）的总裁兼首席执行官（2015年至2018年）。他自2013年2月加入InterMune起担任其执行副总裁兼首席业务官。在加入InterMune前，自2011年8月至2012年12月他在Reata Pharmaceuticals Inc.担任副总裁兼首席商务官。先前自2004年起他在Ovation Pharmaceuticals担任市场营销和销售运营部副总裁。2009年Ovation被丹麦制药公司H. Lundbeck收购。在2009年4月至2010年10月期间领导Ovation的一体化后，他担任首席商务官以及之后Lundbeck新创建美国实体的总裁。他持有来自John Carroll University的生物学文学士学位。
- Sean P. Nolan has to Board 35 years of experience in the life sciences industry as a public company executive, operator and serial entrepreneur. His diverse functional expertise includes commercial operations, global marketing, and corporate and business development. Mr. Nolan previously served as CEO of AveXis (NYSE: AVXS), which he grew from four employees to a fully integrated global public company with research, clinical, regulatory, manufacturing and commercial operations that was ultimately sold to Novartis for $8.7 billion.
高管简历
中英对照 | 中文 | 英文- Sukumar Nagendran
Sukumar Nagendran自2020年7月以来一直担任我们的董事会成员。Nagendran博士自2018年9月起担任生命科学公司Solid BiosciencesInc.的董事会成员，目前担任生物技术公司Encode Therapeutics，Inc.的顾问。在与Immunovant，Inc.合并之前，他曾于2019年3月至2019年12月担任特殊目的收购公司Health Sciences Acquisition Corp.的董事会成员。Nagendran博士最近于2015年9月至2018年5月担任基因治疗公司Avexis，Inc.（Quest Diagnostics Inc.）的高级副总裁兼首席医疗官，此前曾担任临床实验室Quest Diagnostics Inc.美国和国际业务主管Vice President，从2013年3月到2015年9月。Nagendran博士在罗格斯大学（Rutgers University）获得文学学士学位，在新泽西医学和牙科大学（University of Medicine and Dentistry of New Jersey）获得医学硕士学位，并在明尼苏达州罗彻斯特的梅奥诊所（Mayo Clinic）接受内科培训。
Sukumar Nagendran,has served as Taysha Gene Therapies, Inc. President and Head of Research and Development since December 2022 and as a member of Taysha Gene Therapies, Inc. Board of Directors since July 2020. Dr. Nagendran previously served as President, Research and Development and Chief Medical Officer at Jaguar Gene Therapy, LLC, from February 2020 to December 2022. Dr. Nagendran has served on the board of directors of Solid Biosciences Inc., a publicly traded life sciences company, since September 2018 and currently serves as an advisor to Encoded Therapeutics, Inc., a biotechnology company. He previously served on the board of directors of Health Sciences Acquisition Corp., a special purpose acquisition company, from March 2019 to December 2019 prior to its merger with Immunovant, Inc. Dr. Nagendran most recently served as Senior Vice President and Chief Medical Officer of AveXis, Inc., a publicly traded gene therapy company, from 2015 to May 2018. Dr. Nagendran earned a B.A. from Rutgers University and an M.D. from the University of Medicine and Dentistry of New Jersey and trained in Internal Medicine at Mayo Clinic in Rochester, Minnesota.- Sukumar Nagendran自2020年7月以来一直担任我们的董事会成员。Nagendran博士自2018年9月起担任生命科学公司Solid BiosciencesInc.的董事会成员，目前担任生物技术公司Encode Therapeutics，Inc.的顾问。在与Immunovant，Inc.合并之前，他曾于2019年3月至2019年12月担任特殊目的收购公司Health Sciences Acquisition Corp.的董事会成员。Nagendran博士最近于2015年9月至2018年5月担任基因治疗公司Avexis，Inc.（Quest Diagnostics Inc.）的高级副总裁兼首席医疗官，此前曾担任临床实验室Quest Diagnostics Inc.美国和国际业务主管Vice President，从2013年3月到2015年9月。Nagendran博士在罗格斯大学（Rutgers University）获得文学学士学位，在新泽西医学和牙科大学（University of Medicine and Dentistry of New Jersey）获得医学硕士学位，并在明尼苏达州罗彻斯特的梅奥诊所（Mayo Clinic）接受内科培训。
- Sukumar Nagendran,has served as Taysha Gene Therapies, Inc. President and Head of Research and Development since December 2022 and as a member of Taysha Gene Therapies, Inc. Board of Directors since July 2020. Dr. Nagendran previously served as President, Research and Development and Chief Medical Officer at Jaguar Gene Therapy, LLC, from February 2020 to December 2022. Dr. Nagendran has served on the board of directors of Solid Biosciences Inc., a publicly traded life sciences company, since September 2018 and currently serves as an advisor to Encoded Therapeutics, Inc., a biotechnology company. He previously served on the board of directors of Health Sciences Acquisition Corp., a special purpose acquisition company, from March 2019 to December 2019 prior to its merger with Immunovant, Inc. Dr. Nagendran most recently served as Senior Vice President and Chief Medical Officer of AveXis, Inc., a publicly traded gene therapy company, from 2015 to May 2018. Dr. Nagendran earned a B.A. from Rutgers University and an M.D. from the University of Medicine and Dentistry of New Jersey and trained in Internal Medicine at Mayo Clinic in Rochester, Minnesota.
- Kamran Alam
Kamran Alam自2020年8月起担任我们的首席财务官。Alam先生曾于2019年10月至2020年7月担任生物制药公司Rocket制药公司的高级副总裁，财务和首席财务官，并于2016年4月至2019年10月担任基因治疗公司Avexis，Inc.的财务Vice President。从2013年到2016年4月，他在生物制药公司AptinyxInc.担任越来越重要的职务，离职时他是该公司的财务和会计高级总监。Alam先生是一名注册会计师，在密歇根大学罗斯商学院（Ross School of Business at Michigan）获得工商管理学士学位，在印第安纳大学凯利商学院（Kelley School of Business at Indiana）获得金融工商管理硕士学位。
Kamran Alam,has served as Taysha Gene Therapies, Inc. Chief Financial Officer since August 2020. Mr. Alam previously served as Senior Vice President, Finance and Principal Financial Officer of Rocket Pharmaceuticals, Inc., a biopharmaceutical company, from October 2019 to July 2020 and as Vice President, Finance at AveXis, Inc., a publicly traded gene therapy company, from April 2016 to October 2019. From 2013 to April 2016, he held positions of increasing responsibility at Aptinyx Inc., a publicly traded biopharmaceutical company, where at the time of his departure he was a Senior Director, Finance and Accounting. Mr. Alam is a Certified Public Accountant and earned a B.B.A. from the Ross School of Business at University of Michigan and an M.B.A. in finance from the Kelley School of Business at Indiana University.- Kamran Alam自2020年8月起担任我们的首席财务官。Alam先生曾于2019年10月至2020年7月担任生物制药公司Rocket制药公司的高级副总裁，财务和首席财务官，并于2016年4月至2019年10月担任基因治疗公司Avexis，Inc.的财务Vice President。从2013年到2016年4月，他在生物制药公司AptinyxInc.担任越来越重要的职务，离职时他是该公司的财务和会计高级总监。Alam先生是一名注册会计师，在密歇根大学罗斯商学院（Ross School of Business at Michigan）获得工商管理学士学位，在印第安纳大学凯利商学院（Kelley School of Business at Indiana）获得金融工商管理硕士学位。
- Kamran Alam,has served as Taysha Gene Therapies, Inc. Chief Financial Officer since August 2020. Mr. Alam previously served as Senior Vice President, Finance and Principal Financial Officer of Rocket Pharmaceuticals, Inc., a biopharmaceutical company, from October 2019 to July 2020 and as Vice President, Finance at AveXis, Inc., a publicly traded gene therapy company, from April 2016 to October 2019. From 2013 to April 2016, he held positions of increasing responsibility at Aptinyx Inc., a publicly traded biopharmaceutical company, where at the time of his departure he was a Senior Director, Finance and Accounting. Mr. Alam is a Certified Public Accountant and earned a B.B.A. from the Ross School of Business at University of Michigan and an M.B.A. in finance from the Kelley School of Business at Indiana University.
- Sean P. Nolan
Sean P. Nolan，Nolan Capital, LLC（投资基金）总裁，2019年至今。AveXis, Inc.（前纳斯达克股票代码：AVXS）的总裁兼首席执行官（2015年至2018年）。他自2013年2月加入InterMune起担任其执行副总裁兼首席业务官。在加入InterMune前，自2011年8月至2012年12月他在Reata Pharmaceuticals Inc.担任副总裁兼首席商务官。先前自2004年起他在Ovation Pharmaceuticals担任市场营销和销售运营部副总裁。2009年Ovation被丹麦制药公司H. Lundbeck收购。在2009年4月至2010年10月期间领导Ovation的一体化后，他担任首席商务官以及之后Lundbeck新创建美国实体的总裁。他持有来自John Carroll University的生物学文学士学位。
Sean P. Nolan has to Board 35 years of experience in the life sciences industry as a public company executive, operator and serial entrepreneur. His diverse functional expertise includes commercial operations, global marketing, and corporate and business development. Mr. Nolan previously served as CEO of AveXis (NYSE: AVXS), which he grew from four employees to a fully integrated global public company with research, clinical, regulatory, manufacturing and commercial operations that was ultimately sold to Novartis for $8.7 billion.- Sean P. Nolan，Nolan Capital, LLC（投资基金）总裁，2019年至今。AveXis, Inc.（前纳斯达克股票代码：AVXS）的总裁兼首席执行官（2015年至2018年）。他自2013年2月加入InterMune起担任其执行副总裁兼首席业务官。在加入InterMune前，自2011年8月至2012年12月他在Reata Pharmaceuticals Inc.担任副总裁兼首席商务官。先前自2004年起他在Ovation Pharmaceuticals担任市场营销和销售运营部副总裁。2009年Ovation被丹麦制药公司H. Lundbeck收购。在2009年4月至2010年10月期间领导Ovation的一体化后，他担任首席商务官以及之后Lundbeck新创建美国实体的总裁。他持有来自John Carroll University的生物学文学士学位。
- Sean P. Nolan has to Board 35 years of experience in the life sciences industry as a public company executive, operator and serial entrepreneur. His diverse functional expertise includes commercial operations, global marketing, and corporate and business development. Mr. Nolan previously served as CEO of AveXis (NYSE: AVXS), which he grew from four employees to a fully integrated global public company with research, clinical, regulatory, manufacturing and commercial operations that was ultimately sold to Novartis for $8.7 billion.